Andy Scharenberg
Executive Partner at MPM BioImpact
Andy Scharenberg is Chief Executive Officer at Umoja Biopharma and Executive Partner at MPM BioImpact. He co-founded Generation Bio, where he is no longer active. His expertise spans physician-scientist leadership and entrepreneurship in cancer treatment and CAR T-cell therapy.
-
Umoja Biopharma Executive Officer, Director 2021–present · current
-
MPM BioImpact Executive Partner 2019–present · current
-
Umoja Biopharma Chief Executive Officer 2019–present · current
-
Casebia Therapeutics Chief Scientific Officer 2017–2019 · past
-
Generation Bio Co-founder, Chair, Scientific Advisory Board 2017–2025 · past
-
Alpine Immune Sciences Chair, Scientific Advisory Board 2016–2024 · past
-
bluebird bio Scientific Advisory Board member 2014–2017 · past
-
Cellectis therapeutics Chief Scientific Officer 2011–2014 · past
-
Pregenen Co-founder and Member, Board of Directors 2009–2014 · past
-
Seattle Children's Hospital and Research Institute Principal Investigator 2000–2020 · past
-
University of Washington Professor of Pediatrics and Immunology 2000–2020 · past
Education
-
University of North Carolina School of Medicine MD, Medicine · 1991–1993
Organizations
See all 11-
Umoja Biopharma Executive Officer, Director 2021–present · current
-
MPM BioImpact Executive Partner 2019–present · current
-
Umoja Biopharma Chief Executive Officer 2019–present · current
Education
-
University of North Carolina School of Medicine MD, Medicine · 1991–1993
